Although both GIP and GLP-1 possess significant insulinotropic activity, some controversy exists as to their relative physiological roles in stimulating insulin release in response to feeding
Stratified by GLP-1 related and non GLP-1 related treatments In the included RCTs, GLP-1 related drugs (including liraglutide, semaglutide, beinaglutide, exenatide, and AMG133) showed significant weight regain compared with control group (WMD = 1.78 kg, 95% CI 0.76 to 2.80, P = 0.006, I 2 = 85%)
These findings suggest that MET-097 not only induces significant short-term weight loss but also has the potential for durable efficacy with relatively few doses
Licensed from Chugai Pharmaceutical in 2018, orforglipron represents a significant advancement in the treatment of type 2 diabetes and obesity
Low blood sugar (dosage adjustment of diabetes medications may be necessary during phentermine therapy)
Potential Side Effects of Semaglutide and Tirzepatide Both medications share similar side effect profiles